KOSDAQChemicals0007C0

Acryl

₩11,180▲ 4.00%2026-11-18 close
Market Cap
₩89.8B
Turnover
₩300M
Volume
30K
Shares out.
8M
PER
—
PBR
2.3×
EPS
-₩350
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue recovers, but losses persist for three straight quarters

Acryl's quarterly revenue recovered from the first quarter to the third quarter of 2026, but operating losses continued for three straight quarters, making the timing of a profit turnaround the key point to watch.

  1. 1

    Revenue for 2025 was KRW 13.3 billion, down 0.8% from the prior year, and the company posted an operating loss of KRW 2.25 billion, a second straight annual loss with a narrower gap.

  2. 2

    Quarterly revenue reached KRW 6.57 billion in the first quarter of 2026 and KRW 7.92 billion in the third quarter, yet the company still recorded an operating loss of KRW 1.04 billion in the third quarter.

  3. 3

    Total equity at the end of 2025 was KRW 43.7 billion, a sharp change from 2024, when the debt ratio was negative, and total liabilities were KRW 7.19 billion.

  4. 4

    Operating cash flow deteriorated, with the outflow widening from KRW -1.4 billion in 2024 to KRW -4.71 billion in 2025.

  5. 5

    A government R&D project worth about KRW 7.6 billion, running from June 2026 to December 2030, and a healthcare AX contract in Uzbekistan are presented as the medium-term revenue pillars.

02

Business structure

Acryl, founded in 2011, is an AX (AI transformation) infrastructure company that sells business-to-business to enterprises and public institutions.

Its core product is the AI infrastructure platform Jonathan, and it is concentrating development resources on GPUBASE, a GPU cluster optimization software, and NADIA-ANE, an AI-native electronic medical record system.

In healthcare, its NADIA platform processes medical data into a form AI can interpret and is supplied to large domestic hospitals and to Central Asian markets.

Segment mixes differ by aggregator: Butler put the 2026 second-quarter revenue mix at Solution (Jonathan) 59%, government subsidies 29%, services 8% and healthcare solution (NADIA) 3%, while JobKorea, without stating a period, showed Jonathan at 70%, government subsidy income 20%, services 8% and NADIA 2%.

Neither aggregator is a DART filing, so the segment shares should be read as reference only. Because government subsidy income makes up a large share of revenue, the pace of government projects feeds directly into sales.

According to the company profile, it has run more than 200 industry-specialized AX projects across large corporations, central government agencies, public R&D and healthcare.

It is participating as a co-research institution with Korea University Anam Hospital in a Ministry of Science and ICT biomedical multimodal foundation model project worth about KRW 7.6 billion, running from June 2026 to December 2030.

In competition, AI infrastructure software overlaps with cloud and GPU management vendors and hospital information system vendors, and Acryl positions the combination of medical data and AI infrastructure as its differentiator.

It listed on KOSDAQ in December 2025, and the public offering proceeds and capital increase are reflected in its balance sheet.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3———
2025Q4———
2026Q1₩6.6B-₩800M−12.0%
2026Q2₩5.5B-₩1.5B−27.3%
2026Q3₩7.9B-₩1B−13.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩13.4B-₩2.4B-₩5.5B−17.8%—−165.7%
2025₩13.3B-₩2.3B-₩2.8B−16.9%−6.4%16.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On an annual basis, 2025 revenue was KRW 13.3 billion, down 0.8% from KRW 13.4 billion in 2024. Over the same period the operating loss narrowed from KRW 2.39 billion to KRW 2.25 billion, and the operating margin improved slightly from -17.8% to -16.9%.

The company has posted operating losses for two consecutive years, from 2024 through 2025, with the loss gap narrowing.

Net loss attributable to controlling shareholders shrank from KRW 5.47 billion in 2024 to KRW 2.81 billion in 2025, and in 2025 that net loss was larger than the operating loss, meaning non-operating items widened the loss.

Net loss including non-controlling interests was also reported at KRW 5.47 billion in 2024 and KRW 2.81 billion in 2025, the same amounts as the controlling-shareholder figures.

Total equity at the end of 2025 was KRW 43.7 billion, all attributable to controlling shareholders, and total liabilities were KRW 7.19 billion. The debt ratio moved from -165.7% in 2024 to 16.4% in 2025, and the negative 2024 figure indicates that total equity was negative at that time.

Operating cash flow worsened, with the outflow widening from KRW -1.4 billion in 2024 to KRW -4.71 billion in 2025. Within 2026, first-quarter revenue was KRW 6.57 billion, with an operating loss of KRW 786 million and a net loss attributable to controlling shareholders of KRW 695 million.

In a release dated May 18, 2026, the company said first-quarter revenue rose 123% from a year earlier. Second-quarter revenue was KRW 5.47 billion, down 16.7% from the prior quarter, and the operating loss widened to KRW 1.5 billion.

Third-quarter revenue rose 44.6% from the prior quarter to KRW 7.92 billion, while the operating loss narrowed to KRW 1.04 billion and the net loss attributable to controlling shareholders narrowed to KRW 1.11 billion.

The company has recorded losses in each of the three quarters from the first quarter to the third quarter of 2026. The company attributes the expected easing of fixed-cost pressure to operating leverage from a larger revenue base.

Quarterly figures for the third and fourth quarters of 2025 are not in the periodic filings, so quarterly comparisons are limited to 2026. The net loss attributable to controlling shareholders for the last four quarters, from the first quarter to the fourth quarter of 2025, totaled KRW 2.81 billion.

05

Industry analysis

Acryl's end demand comes from enterprises and public institutions adopting AI, especially efforts to improve the efficiency of GPU-based infrastructure. The company said it is widening validation beyond NVIDIA GPUs to domestic NPU and DPU environments.

The government has named healthcare as a priority area for AI adoption, and press coverage described this as expanding growth opportunities for companies with medical AI technology.

The company says infrastructure adoption is gaining momentum in both public and private sectors as participation in government-led AX projects increases. Demand appears to be broadening from public R&D to large hospitals and major telecom operators.

Chemical peers in the same listed category, such as LG Chem, Hanwha Solutions and Lotte Chemical, have earnings tied to petrochemical and materials cycles, whereas Acryl's revenue comes from software and infrastructure, so its link to chemical industry indicators is weak.

Data sites, however, classify the company as application software, so the relevant comparison set depends on which classification is used. Its competitive position rests on AI infrastructure combined with medical data and on an overseas base built on medical IT references in Uzbekistan.

06

Outlook

When announcing first-quarter 2026 results, the company said growth seen in the first quarter would continue into the second quarter.

In the same release it reported first-quarter orders of KRW 20.7 billion, up 86% from a year earlier, and expected faster earnings improvement in the second half as the order backlog grows and new customers, including a major telecom operator, come on board.

Second-quarter revenue actually fell to KRW 5.47 billion from the prior quarter, and third-quarter revenue recovered to KRW 7.92 billion, so the second-quarter outlook and the actual quarterly path diverged.

On the product side, upgrades to GPUBASE, the GPU cluster optimization software, and NADIA-ANE, the AI-native EMR, were cited as the main priorities this year, with application expanding from hospitals to biotech, green bio and pharmaceutical companies.

The Ministry of Science and ICT project runs from June 2026 to December 2030 and builds an AI model that integrates pathology imaging, genetic and protein information, and EEG data.

The company said the project will extend its medical AI scope from electronic medical records and text analysis to pathology imaging, biomolecular information and EEG-based analysis.

Overseas, it signed a definitive healthcare AX contract with Uzinfocom, a state-owned Uzbek IT company, and plans to co-design a next-generation hospital information system platform, build a local AI healthcare R&D base and jointly review medical device software approval procedures.

The next checkpoints are the pace at which the order backlog converts into revenue by the fiscal year-end on December 31, 2026, and the full-year operating loss that will appear in the 2026 annual report.

07

Valuation

PER
—
PBR
2.3×
ROE
-6.4%
EPS
-₩350
BPS
₩5,124
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, its price-to-earnings ratio cannot be calculated. On a net-asset basis, the price-to-book ratio sits in a range carrying a premium over book value.

The net-asset base is total equity of KRW 43.7 billion at the end of 2025, all of it attributable to controlling shareholders. Since the listing enlarged the equity base, the book-value ratio reflects the capital raised in the offering. The dividend yield is below the industry average.

Because earnings have not yet turned positive, comparisons based on earnings multiples are limited, and the meaning of valuation metrics will shift depending on when profitability returns.

Over several years, losses narrowed from 2024 to 2025 and quarterly revenue scale grew in 2026, but operating losses moved up and down quarter to quarter, so the recovery in earnings is confirmed only as a direction at this stage.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Recovery in revenue scale

According to the company, first-quarter 2026 revenue rose 123% from a year earlier to KRW 6.57 billion. Third-quarter revenue reached KRW 7.92 billion, up 44.6% from the prior quarter. First-quarter orders reached KRW 20.7 billion, up 86% from a year earlier.

Expanding government projects and public demand

The company is taking part in a Ministry of Science and ICT biomedical multimodal foundation model project with a total budget of about KRW 7.6 billion. The project runs from June 2026 to December 2030 and could serve as a base for medium-term revenue. Government designation of healthcare as a priority AI area is cited as a backdrop for wider public demand.

Overseas footprint taking shape

The company said it signed a definitive healthcare AX contract with Uzinfocom, a state-owned Uzbek IT company. The two sides plan to co-develop a next-generation hospital information system platform and set up a local R&D base. The company said it intends to use this as a launchpad for healthcare AX in Central Asia.

09

Bear factors

Three straight quarters of operating losses

Operating losses were KRW 790 million in the first quarter of 2026 and KRW 1.5 billion in the second quarter, when they widened, before narrowing to KRW 1.04 billion in the third quarter.

Net losses attributable to controlling shareholders were KRW 695 million, KRW 1.53 billion and KRW 1.11 billion across the three quarters. Revenue growth has not yet brought the business to breakeven.

Wider operating cash outflow

The cash drained by operating activities grew within a year, widening the deficit. The larger outflow in the year the company listed highlights the burden of investment. Even with total equity of KRW 43.7 billion, the financial cushion narrows if operations do not generate cash.

Non-operating losses and quarterly volatility

In 2025 the net loss attributable to controlling shareholders of KRW 2.81 billion exceeded the operating loss of KRW 2.25 billion, so non-operating items widened the loss. Second-quarter 2026 revenue fell 16.7% from the prior quarter, showing quarterly volatility. Quarterly comparisons cover only 2026, so the trend record is short.

10

Risk factors

Dependence on government projects and subsidies

Aggregator data show government subsidy income making up a sizable share of revenue. A cut in project budgets or a change in project timing could disrupt revenue flow. Faster growth in commercial revenue would ease this exposure.

Medical AI regulation and data issues

The medical AI business is subject to approval rules for medical device software and to regulations on handling medical data. The company is reviewing approval procedures with an overseas partner, and regulatory changes at home or abroad could affect product launch timing. Expanding into pathology imaging and EEG data raises the regulatory workload as well.

Funding needs and cost of expansion

Operating cash outflows continue while upgrades to GPUBASE and NADIA-ANE and overseas base building proceed at the same time. If expansion costs grow faster than revenue recovery, additional funding may be needed.

Because operating losses have moved up and down each quarter, the effect of cost control is still at an early stage.

11

What to watch next

  1. December 31, 2026

    Fiscal year-end, a reference point for checking how much of the KRW 20.7 billion in first-quarter orders and the order backlog converts into revenue.

  2. Late March 2027

    The deadline for the 2026 annual report, when full-year 2026 revenue and operating loss and fourth-quarter figures are confirmed as DART-filed results.

  3. Mid-May 2027

    The deadline for the first-quarter 2027 quarterly report, a checkpoint for whether the streak of operating losses that began in the first quarter of 2026 comes to an end.

12

Overall view

Acryl operates a business that combines AI infrastructure software with medical AI, and quarterly revenue showed a recovery trend in 2026. First-quarter revenue of KRW 6.57 billion, third-quarter revenue of KRW 7.92 billion and first-quarter orders of KRW 20.7 billion are the strengths on the top-line side.

On the other side, operating losses have continued for three straight quarters from the first quarter to the third quarter of 2026, and the operating cash outflow widened in 2025.

The government project worth about KRW 7.6 billion and the definitive Uzinfocom contract are cited as medium-term revenue foundations, but the scale confirmed in reported results is still limited.

Valuation is hard to compare on earnings because the company is loss-making, and on a net-asset basis the stock sits in a range carrying a premium over book value.

The next checkpoints are the full-year operating loss in the 2026 annual report and whether operating losses continue in the first-quarter 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. butler.works
  2. eugenefn.com
  3. accidentalorder.com
  4. news.nate.com
  5. news.nate.com
  6. sedaily.com
  7. fairvalueresearch.net
  8. m.news.zum.com
  9. jobkorea.co.kr
  10. tradingkey.com
  11. tradingkey.com
  12. kr.investing.com
  13. globenewswire.com
  14. finance.yahoo.com
  15. morningstar.com
  16. manilatimes.net
  17. tradingkey.com
  18. indexbox.io

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis